Sumitomo Dainippon Pharma Annual Report 2017
21/102

LATUDA® (lurasidone hydrochloride) is an atypical antipsychotic agent that is believed to have an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects. In addition, LATUDA® is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine H1 or muscarinic M1 receptors.SEP-225289 is a dopamine and norepinephrine reuptake inhibitor (DNRI). SEP-225289 has an extended half-life (47-77 hours) that supports the potential for a continuous therapeutic effect by dosing at 24-hour intervals.APL-130277 is a sublingual film formulation of apomorphine, a dopamine agonist, which is the only molecule approved in the U.S. for acute intermittent treatment of OFF episodes associated with Parkinson’s disease. It is designed to rapidly, safely and reliably convert a Parkinson’s disease patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine.BBI608 is an orally administered small molecule agent with a novel mechanism of action designed to inhibit cancer stemness pathways by targeting STAT3. By inhibiting pathways involved in the maintenance of cancer stemness, it may provide a new therapeutic option against the challenges in cancer treatment such as treatment resistance, recurrence and metastasis.BBI503 is an orally administered small molecule agent with a novel mechanism of action designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases. By inhibiting pathways involved in the maintenance of cancer stemness, it may provide a new therapeutic option against the challenges in cancer treatment such as treatment resistance, recurrence and metastasis.DSP-7888 is a therapeutic cancer peptide vaccine derived from Wilms’ tumor gene 1 (WT1) protein. DSP-7888 is a vaccine containing peptides that induces WT1-specific cytotoxic T lymphocytes (CTLs) and helper T cells. DSP-7888 is expected to become a treatment option for patients with various types of hematologic malignancies and solid tumors that express WT1, by inducing WT1-specific CTLs that attack WT1-expressing cancer cells. By adding a helper T cell-inducing peptide, improved efficacy over that observed with a killer peptide alone may be achieved.Alvocidib targets cyclin-dependent kinase (CDK) 9, a member of cyclin-dependent kinase family, which activates transcription of cancer-related genes. The subsequent down-regulation of MCL-1, an anti-apoptotic gene, may be responsible for the potential clinical anti-cancer activity observed with alvocidib.LATUDA® (lurasidone hydrochloride)Atypical antipsychotic Developed in-houseDasotraline (SEP-225289)Attention-deficit hyperactivity disorder (ADHD), Binge eatingdisorder (BED) Developed in-house (Sunovion Pharmaceuticals Inc.)Apomorphine hydrochloride (APL-130277)Parkinson’s disease Developed in-house (Sunovion PharmaceuticalsInc., from former Cynapsus Therapeutics)Napabucasin (BBI608)Cancer Developed in-house (Boston Biomedical, Inc.)Amcasertib (BBI503)Cancer Developed in-house (Boston Biomedical, Inc.)DSP-7888Cancer Developed in-houseAlvocidibCancer In-licensed from Sanofi S.A.LONASEN®(Schizophrenia /Transdermal patch)LONASEN®(Schizophrenia)(Approved in Feb.2017)amcasertib(Solid tumors)amcasertib(Solid tumors)DSP-7888(Solid tumors /Hematologic malignancies)dasotraline(BED)SB623(Chronic stroke)DSP-2230(Neuropathic pain)SEP-363856(Schizophrenia)obeticholic acid(NASH)DSP-7888(Solid tumors /Hematologic malignancies)napabucasin(Colorectal cancer, Pancreatic cancer)DSP-6952(IBS with constipation,Chronic idiopathic constipation)iPS cell-derived RPE cells(Age-related macular degeneration)dasotraline(ADHD)apomorphine(Parkinson’s disease)lurasidone(Schizophrenia)glycopyrronium(COPD)UTIBRONTM, SEEBRITM (COPD)(In-licensed)thiotepa(Conditioning treatmentprior to HPCT)napabucasin(Colorectal cancer,Pancreatic cancer)alvocidib(Acute myeloid leukemia)TRERIEF®(Parkinsonism in Dementiawith Lewy Bodies)lurasidone(Schizophrenia / Bipolar ldepression / Bipolar maintenance)Psychiatry & NeurologyOncologyRespiratoryLiver / DigestiveNew Chemical EntitiesNew Indication, etc.FY2017FY2018FY2019FY2020 - FY2022JapanU.S.ChinaAreaCandidates for delivering sustainable growth —Striving for a quick recovery from the “LATUDA cliff”—Product Launch Plan (as of July 28, 2017)20Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#21

このブックを見る